What Happens After a GDP Audit? Managing Findings, CAPA and Remediation

Receiving the final report after a Good Distribution Practice (GDP) audit is not the end of the process. It marks the start of the remediation phase that determines whether findings are closed superficially or used to strengthen the quality system. For wholesale distributors, logistics providers and Responsible Persons (RPs), the audit report highlights vulnerabilities in storage, transit, supplier oversight and documentation. Treating those findings as administrative tasks to be closed quickly often leads to recurrence. A structured, risk-based approach converts them into lasting improvements in supply-chain integrity.

This article focuses specifically on the post-report stage: how to categorise findings, run effective CAPA investigations, demonstrate effectiveness, and fulfil the RP’s responsibilities in a distribution environment. While Corrective and Preventive Action (CAPA) is a regulatory expectation under pharmaceutical quality systems, the investigation techniques described below are industry best practice used to meet that expectation effectively.

Categorising and Prioritising GDP Audit Findings

The first task after receiving the report is to classify every finding according to its potential impact on product quality and patient safety. MHRA and EU GDP inspection practice grades deficiencies as Critical, Major or Other. Official definitions are set out in the MHRA guidance on good manufacturing practice and good distribution practice:

• Critical: A deficiency which has produced, or significantly risks producing, a product that is harmful to patients, or any departure from GDP that results in a significant risk to patients. This includes activities that increase the risk of falsified medicines reaching patients. Immediate containment is required.
• Major: A non-critical deficiency that indicates a major deviation from GDP or from the terms of the wholesale distribution authorisation, or that has caused or may cause a medicinal product not to comply with its marketing authorisation (particularly storage and transport conditions). It may also arise from a combination of several Other deficiencies.
• Other: A deficiency that cannot be classified as Critical or Major but still indicates a departure from GDP guidelines.

Immediate containment must be distinguished from longer-term systemic action. In a distribution setting this frequently means:

• Physically and securely segregating any suspect or rejected medicinal products from saleable stock.
• Quarantining affected batches or routes until the Responsible Person has assessed the risk and decided on disposition (return to saleable stock, rejection, recall or disposal).
• Temporarily suspending a transit lane or third-party logistics (3PL) route where temperature control or security cannot be assured.

The Responsible Person remains accountable for these decisions and for ensuring that any subsequent recall or disposal is managed in accordance with written procedures and, where required, notified to the competent authority. Critical findings typically require faster containment and CAPA planning than Major or Other observations. Significant breaches, systemic failures, or situations that may affect patient safety or product availability often require formal notification to the MHRA; the RP must decide whether notification is necessary based on the nature and impact of the finding.

From Findings to Formal CAPA: The Remediation Lifecycle

A common failure is to stop at the immediate correction — updating a temperature log, re-training a single driver, or amending one shipping document. These actions address the symptom. Effective CAPA requires identification of the root cause so the non-conformance does not recur.

Root-cause analysis should be proportionate to the risk and tailored to distribution operations. Typical techniques such as the 5 Whys, fishbone diagrams or process mapping are industry best practice. They are not mandated methods, but they are the tools most organisations use to satisfy the regulatory expectation for thorough investigation.

Example 1 – Temperature excursion on a 3PL lane
An audit identifies repeated temperature excursions on a validated cold-chain lane operated by a third-party logistics provider. Immediate containment may involve segregating the affected stock and placing the lane on hold. The investigation should examine whether the transit lane qualification remains current, the placement and calibration of data loggers, communication protocols when alarms occur, and the adequacy of the supplier qualification and ongoing performance monitoring programme within the pharmaceutical supply chain.

Example 2 – Documentation and returns handling
A finding shows that returned medicinal products were not consistently segregated or that disposition decisions were not clearly recorded and approved by the RP. The root-cause investigation should look beyond the individual incident to whether procedures are unclear, training is inadequate, or the QMS does not enforce RP approval before stock is returned to saleable status.

Only once the root cause is established can corrective actions (eliminate the cause) and preventive actions (stop recurrence elsewhere) be defined, assigned and given clear timelines within the QMS. The resulting CAPA record must clearly document the link between the original finding, the root-cause investigation, the corrective and preventive actions taken, evidence of completion, and the subsequent effectiveness check. This full chain of evidence forms the audit trail that inspectors will review.

When preparing the formal response to the inspection report, organisations should follow the structure and expectations set out in the MHRA guidance on responding to a GMP/GDP post-inspection letter. Clear timelines, root-cause statements and measurable actions help close the process efficiently.

Demonstrating CAPA Effectiveness to the MHRA

Closing a CAPA is not the same as proving it worked. Regulators expect evidence that the underlying issue has been resolved and has not recurred.

Effectiveness criteria should be defined at the outset and linked to the root cause. In the temperature-excursion example, completion of a new mapping study alone is insufficient. Effectiveness is demonstrated by reviewing subsequent shipment data over a defined period (for example 30–90 days, depending on volume and risk) to confirm that temperature profiles remain within the validated range, and by verifying that the 3PL’s response to any alarms meets the agreed protocol. The evidence should be retained in the QMS and available for inspection.

Where effectiveness relies on electronic records or monitoring systems, the reliability of those systems becomes relevant. Organisations that have validated their computerised systems in line with data-integrity expectations are better placed to provide credible evidence. Further guidance is available in our resource on how CSV services enhance data integrity and compliance in pharma.

Verification methods should be risk-based: enhanced monitoring, targeted internal audits, or trend analysis of related deviations. All evidence should be retained within the QMS so that the full remediation history is available for inspection.

Common Pitfalls and the Role of the Responsible Person

The most frequent weakness is the “band-aid” fix — re-training staff without examining why the original training failed, or updating an SOP without checking whether the process itself is workable under operational pressure. These superficial corrections rarely survive the next inspection.

The Responsible Person is legally accountable for GDP compliance and must exercise active oversight throughout the remediation process. This includes challenging weak root-cause analyses, ensuring that CAPAs are closed only with appropriate evidence, and deciding whether a finding or the resulting actions require formal notification to the MHRA. Failure to report significant breaches or systemic failures can itself become a regulatory issue.

Beyond individual findings, the audit report should be treated as diagnostic information. When lessons are embedded into the wider Quality Management System and into supplier and transit controls, the organisation moves from reactive compliance to sustained control of the distribution network. For further context on how GDP requirements differ from manufacturing controls, see our comparison of GDP vs GMP.

Practical Steps for Closing Findings Effectively

A practical remediation sequence that many distribution organisations find useful is:

1. Acknowledge receipt of the report and allocate clear ownership for each finding.
2. Complete immediate containment and risk assessment (RP-led).
3. Perform proportionate root-cause analysis and document it fully.
4. Define corrective and preventive actions with realistic timelines and responsible persons.
5. Implement the actions and gather objective evidence of completion.
6. Define and execute effectiveness checks linked to the original risk.
7. Close the CAPA only when effectiveness is demonstrated and the record is inspection-ready.
8. Review the wider QMS for systemic implications and update related procedures, training or supplier controls as needed.

This sequence keeps the process disciplined while remaining flexible enough for the operational realities of wholesale distribution and logistics.

Conclusion

Managing the aftermath of a GDP audit is a core part of maintaining supply-chain integrity. Clear categorisation using official grading criteria, rigorous root-cause investigation, measurable effectiveness checks, and active RP oversight turn findings into lasting improvements rather than recurring observations.

Complex or systemic issues — particularly those involving third-party logistics, temperature control or supplier qualification — can be difficult to resolve with internal resources alone. Inglasia Pharma Solutions provides practical support through GDP auditing services, including assistance with CAPA investigation, root-cause analysis, QMS integration and inspection readiness. If you need experienced support to close findings effectively and strengthen your distribution controls, contact us to discuss how we can help.